Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study
-
Published:2021
Issue:1
Volume:64
Page:
-
ISSN:0924-9338
-
Container-title:European Psychiatry
-
language:en
-
Short-container-title:Eur. Psychiatr.
Author:
Erzin Gamze, Pries Lotta-Katrin, van Os JimORCID, Fusar-Poli LauraORCID, Delespaul Philippe, Kenis Gunter, Luykx Jurjen J.ORCID, Lin Bochao D., Richards Alexander L., Akdede Berna, Binbay Tolga, Altınyazar Vesile, Yalınçetin Berna, Gümüş-Akay GüvemORCID, Cihan Burçin, Soygür Haldun, Ulaş Halis, Cankurtaran Eylem Şahin, Kaymak Semra Ulusoy, Mihaljevic Marina M., Andric-Petrovic Sanja, Mirjanic Tijana, Bernardo MiguelORCID, Mezquida GiselaORCID, Amoretti Silvia, Bobes JulioORCID, Saiz Pilar A., García-Portilla Maria Paz, Sanjuan Julio, Aguilar Eduardo J., Santos Jose Luis, Jiménez-López Estela, Arrojo Manuel, Carracedo Angel, López Gonzalo, González-Peñas Javier, Parellada Mara, Maric Nadja P., Atbaşoğlu Cem, Ucok Alp, Alptekin Köksal, Saka Meram Can, Arango Celso, O’Donovan Micheal C., Rutten Bart P. F., Guloksuz SinanORCID,
Abstract
Abstract
Background
A cumulative environmental exposure score for schizophrenia (exposome score for schizophrenia [ES-SCZ]) may provide potential utility for risk stratification and outcome prediction. Here, we investigated whether ES-SCZ was associated with functioning in patients with schizophrenia spectrum disorder, unaffected siblings, and healthy controls.
Methods
This cross-sectional sample consisted of 1,261 patients, 1,282 unaffected siblings, and 1,525 healthy controls. The Global Assessment of Functioning (GAF) scale was used to assess functioning. ES-SCZ was calculated based on our previously validated method. The association between ES-SCZ and the GAF dimensions (symptom and disability) was analyzed by applying regression models in each group (patients, siblings, and controls). Additional models included polygenic risk score for schizophrenia (PRS-SCZ) as a covariate.
Results
ES-SCZ was associated with the GAF dimensions in patients (symptom: B = −1.53, p-value = 0.001; disability: B = −1.44, p-value = 0.001), siblings (symptom: B = −3.07, p-value < 0.001; disability: B = −2.52, p-value < 0.001), and healthy controls (symptom: B = −1.50, p-value < 0.001; disability: B = −1.31, p-value < 0.001). The results remained the same after adjusting for PRS-SCZ. The degree of associations of ES-SCZ with both symptom and disability dimensions were higher in unaffected siblings than in patients and controls. By analyzing an independent dataset (the Genetic Risk and Outcome of Psychosis study), we replicated the results observed in the patient group.
Conclusions
Our findings suggest that ES-SCZ shows promise for enhancing risk prediction and stratification in research practice. From a clinical perspective, ES-SCZ may aid in efforts of clinical characterization, operationalizing transdiagnostic clinical staging models, and personalizing clinical management.
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|